A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Latest Information Update: 17 Jun 2025
At a glance
- Drugs AB 101 Artiva Biotherapeutics (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atriva Therapeutics
Most Recent Events
- 11 Jun 2025 Planned End Date changed from 1 Oct 2026 to 1 Aug 2027.
- 11 Jun 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Aug 2027.
- 29 Aug 2024 According to an Artiva Biotherapeutics media release, the company expect to report initial data on autoimmune indications from at least one of the Phase 1/1b trial or the basket IIT in the first half of 2025.